博瑞医药：2025年净利润预降67.28%-78.17%，多在研药有进展

Core Viewpoint - The company, Borui Pharmaceutical, anticipates a significant decline in its annual net profit for 2025, projecting a range of 41.3 million to 61.9 million yuan, which represents a year-on-year decrease of 67.28% to 78.17% [1] Financial Performance - The expected non-GAAP net profit is forecasted to be between 430,000 and 2.49 million yuan, reflecting a year-on-year reduction of 86.21% to 97.62% [1] - The decline in revenue and gross profit is attributed to changes in flu trends, competitive landscape, and customer demand [1] Operational Factors - Increased depreciation from construction projects being put into service and heightened R&D investments are contributing to the profit decline [1] Research and Development - The company has multiple ongoing research projects, including the completion of patient enrollment for the Phase III clinical trials of BGM0504 injection for type 2 diabetes and weight loss in China [1] - The oral BGM0504 tablet is also undergoing Phase I clinical trials in both China and the United States [1] - However, the commercialization of innovative drugs remains uncertain as they are still in the early stages of development [1]